Dr Linda Hoffmann
A medical researcher from Germany has won a fellowship at Sydney to work on a project that looks into the drug fenofibrate's remarkable success in treating diabetes and cardiovascular disease. Clinical trials have shown that fenofibrate, a commonly available drug,drastically reduces the need for laser eye surgery and lower limb amputations in patients with Type 2 diabetes, and is also beneficial when used by cardiovascular patients. The drug's effectiveness is being investigated by postdoctoral researcher Linda Hoffmann, who has started work at the University after being awarded a Feodor Lynen Fellowship by the Alexander von Humboldt Foundation. She will be working with Professor Roland Stocker, the Chair of Biochemistry in Vascular Medicine, and Professor Antony Keech, Deputy Director of the NHMRC Clinical Trials Centre. Dr Hoffmann studied biology at Bochum and gained an MSc in biomedicine at Mainz, investigating a mutation in a protein which can lead to the development of myeloproliferative disorders. "During my studies the importance of investigating diseases as well as drug actions became the focus of my scientific work,"she said. "I decided to apply to Bayer Schering Pharma AG in Wuppertal for a PhD scholarship and luckily my supervisor gave me the opportunity to work in his lab.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
